Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.